

Journal Cover Stories

- 1) Kinam Park: All nanocarriers are created equal. *J. Control. Release* 130: 139, 2008.
- 2) Kinam Park: Bioresponsive drug delivery for regenerative medicine. *J. Control. Release* 130: 201, 2008.
- 3) Kinam Park: Solid-in-oil nanodispersion shows a possibility of transdermal protein delivery. *J. Control. Release* 131: 1, 2008.
- 4) Kinam Park: Understanding skin architecture: a two photon microscopy study. *J. Control. Release* 132: 1, 2008.
- 5) Kinam Park: Trojan monocytes for improved drug delivery to the brain, *J. Control. Release* 132: 75, 2008.
- 6) Kinam Park: Ultrasound-activatable drug-loaded microbubbles for intracellular targeting, *J. Control. Release* 132: 151, 2008.
- 7) Kinam Park: Better design of drug-eluting stents using computer modeling, *J. Control. Release* 133: 1, 2008.
- 8) Kinam Park: A new method for preventing restenosis: A single IV injection of drug-loaded nanoparticles, *J. Control. Release* 133: 87, 2009.
- 9) Kinam Park: Dendrimer polymeric micelles for enhanced photodynamic cancer treatment, *J. Control. Release* 133: 171, 2009.
- 10) Kinam Park: Lectin-immobilized nanospheres for GI tumor targeting, *J. Control. Release* 134: 1, 2009.
- 11) Kinam Park: Non-ionic polymersomes for delivery of oligonucleotides, *J. Control. Release* 134: 73, 2009.
- 12) Kinam Park: Non-invasive monitoring of BMP-2 retention and bone formation, *J. Control. Release* 134: 157, 2009.
- 13) Kinam Park: Smart nanobombs for inducing traumatic death of cancer cells, *J. Control. Release* 135: 1, 2009.
- 14) Kinam Park: Dynamic control of needle-free jet injection, *J. Control. Release* 135: 103, 2009.
- 15) Kinam Park: Self-exploding microcapsules for pulsed drug delivery, *J. Control. Release* 135: 185, 2009.
- 16) Kinam Park: Octaarginine-liposomes as an effective vaccine carrier for mature dendritic cells, *J. Control. Release* 136: 1, 2009.
- 17) Kinam Park: Non viral vector delivery in vitro using fibrin hydrogels, *J. Control. Release* 136: 87, 2009.
- 18) Kinam Park: Targeting to retina by submicron-sized liposomes, *J. Control. Release* 136: 171, 2009.

- 19) Kinam Park: Transport across the blood-brain barrier using albumin nanoparticles, *J. Control. Release* 137: 1, 2009.
- 20) Kinam Park: Real time tracking of single magnetic lipoplex particles in living cells, *J. Control. Release* 137: 89, 2009.
- 21) Kinam Park: Xenogeneic delivery of therapeutic products using transient immunosuppression, *J. Control. Release* 137: 173, 2009.
- 22) Kinam Park: Confocal Raman spectroscopy to study in vivo skin penetration of retinol, *J. Control. Release* 138:1, 2009.
- 23) Kinam Park: Enhanced mucosal vaccination by biodegradable nanoparticles, *J. Control. Release* 138: 89, 2009.
- 24) Kinam Park: Selective synovectomy using thrombin-sensitive photodynamic agents, *J. Control. Release* 138: 224, 2009.
- 25) Kinam Park: Intracellular trafficking of cell-penetrating peptide-avidine complexes, *J. Control. Release* 139: 87, 2009.
- 26) Kinam Park: Dry coating of immunotherapeutics to densely packed and short microprojection arrays, *J. Control. Release* 139: 171, 2009.
- 27) Kinam Park: PEI–DNA complexes with higher transfection efficiency and lower cytotoxicity, *J. Control. Release* 140, 1, 2009.
- 28) Kinam Park: Nanovehicles for enhanced oral delivery of taxanes, *J. Control. Release* 140, 77-78, 2009.
- 29) Kinam Park, You Han Bae, and David W. Grainger: Preface. The 14th International Symposium on Recent Advances in Drug Delivery Systems, February 15–18, 2009, Salt Lake City, UT, USA, *J. Control. Release* 140, 183-184, 2009
- 30) Wim Hennink and Kinam Park: The influence of polymer topology on pharmacokinetics, *J. Control. Release* 140, 185, 2009.
- 31) Kinam Park: Target cell-specific transgene expression delivery systems, *J. Control. Release* 141, 1, 2009.
- 32) Kinam Park: Luciferin liposomes for enhanced in vivo bioluminescence, *J. Control. Release* 141, 109, 2010.
- 33) Daan J.A. Crommelin, Kinam Park, and Alexander Florence: Pharmaceutical nanotechnology: Unmet needs in drug delivery, *J. Control. Release* 141, 263-264, 2010.
- 34) Kinam Park: Endocytic uptake and intracellular trafficking of poly(amidoamine)s, *J. Control. Release* 142, 1, 2010.
- 35) Kinam Park: To PEGylate or not to PEGylate, that is not the question, *J. Control. Release* 142, 147-148, 2010.

- 36) Kinam Park: Systemic siRNA Delivery Using Biocompatible Calcium Phosphate Nanoparticles, *J. Control. Release* 142, 295, 2010.
- 37) Kinam Park: Monitoring intracellular degradation of exogenous DNA by FCS and FCCS, *J. Control. Release* 143, 1, 2010.
- 38) Kinam Park: Tumor regression after systemic administration of transferrin-targeted TNF α plasmid-dendrimer conjugates, *J. Control. Release* 143, 167, 2010.
- 39) Kinamm Park: Efficient delivery of VEGF via heparin-functionalized nanoparticle–fibrin complex, *J. Control. Release* 143, 281, 2010.
- 40) Kinam Park: Safe and effective gene delivery by hybrid polymer-virus vectors, *J. Control. Release* 144, 1, 2010.
- 41) Kinam Park: Nano is better than micro for targeted vaccine delivery, *J. Control. Release* 144, 117, 2010.
- 42) Kinam Park: *In vivo* MRI analysis of intracellular trafficking of paramagnetically labeled liposomes, *J. Control. Release* 144, 269, 2010.
- 43) Kinam Park: Efficient oral delivery of paclitaxel using cyclodextrin complexes, *J. Control. Release* 145, 1, 2010.
- 44) Kinam Park: A new ligand for targeted drug delivery to tumor stromal cells, *J. Control. Release* 145, 75, 2010.
- 45) Kinam Park: Drug release coating for reduced tissue reaction to implanted neuroprostheses, *J. Control. Release* 145, 177, 2010.
- 46) Kinam Park: Positron emission tomography imaging for study of intestinal insulin absorption, *J. Control. Release* 146, 1, 2010.
- 47) Ralph Lipp, Randall Mrsny, and Kinam Park: Seventh International Nanomedicine and Drug Delivery Symposium (NanoDDS'09), *J. Control. Release* 146, 163, 2010.
- 48) Kinam Park: Focused ultrasound for targeted nanoparticle delivery to tumors, *J. Control. Release* 146 (2010) 263.
- 49) Kinam Park: Carbonate apatite-facilitated intracellular delivery of siRNA, *J. Control. Release* 147 (2010) 1.
- 50) Kinam Park: Critical role of molecular imaging for substantially improved anticancer therapy, *J. Control. Release* 147 (2010) 153.
- 51) Kinam Park: Effect of shape and size of polymer particles on cellular internalization, *J. Control. Release* 147 (2010) 313.
- 52) Kinam Park: Paclitaxel-loaded nanoparticles by temperature-induced phase transition, *J. Control. Release* 148 (2010) 265.

- 53) Kinam Park: Achilles heels and Trojan horses against drug-resistant tumor cells, *J. Control. Release* 149 (2010) 91.
- 54) Kinam Park: Enhanced delivery to endothelial lysosomes by ICAM-1-targeted nanocarriers, *J. Control. Release* 149 (2011) 207-208.
- 55) Kinam Park: Selective endothelial targeting of stealthed adenovirus, *J. Control. Release* 150 (2011) 127.
- 56) Kinam Park: Noninvasive imaging of MT1-MMP-positive tumors, *J. Control. Release* 150 (3) (2011) 237.
- 56) Kinam Park: Systemic anti-tumor activity of liposomal glucocorticoids, *J. Control. Release* 151 (1) (2011) 1.
- 57) Kinam Park: Mechanism of cross-presentation of microencapsulated antigen, *J. Control. Release* 151 (3) (2011) 219.
- 58) Kinam Park: Injectable hyaluronic acid hydrogel for bone augmentation, *J. Control. Release* 152 (2) (2011) 207.
- 59) Kinam Park: Improving the reach of vaccines to low-resource regions with a needle-free vaccine delivery device and long-term thermostabilization, *J. Control. Release* 152 (3) (2011) 329.
- 60) Kinam Park: Unraveling the penetration: Model giant plasma membrane vesicles for study of cell-penetrating peptides, *J. Control. Release* 153 (2) (2011) 105.
- 61) Kinam Park: Hexagonal prism nanocarriers for mitigated phagocytosis, *J. Control. Release* 154 (1) (2011) 1.
- 62) Kinam Park: Administration route and carrier dependent effects on vaccine efficacy: Implications for vaccine design, *J. Control. Release* 154 (2) (2011) 109.
- 63) Kinam Park: Shockwave-ruptured nanopayload carriers (SHERPAs) for ultrasound-triggered drug release, *J. Control. Release* 155 (3) (2011) 343.
- 64) Kinam Park: Nanocomposite microparticles for injectable cell scaffolds, *J. Control. Release* 156 (1) (2011) 1.
- 65) Kinam Park: Cardioprotective properties of Tat-BH4 and Pip2b-BH4 in vivo, *J. Control. Release* 156 (2) (2011) 117.
- 66) Kinam Park: IVIVC for circulation kinetics of liposomes, *J. Control. Release* 156 (2011) 275.
- 67) Kinam Park: Albumin: A versatile carrier for drug delivery, *J. Control. Release* 157 (2011) 3.
- 68) Kinam Park: Microbubble ultrasound-guided targeted delivery to tumors, *J. Control. Release* 157 (2011) 167.
- 69) Kinam Park: The optimal formulation variables for tumor targeting, *J. Control. Release* 157 (2011) 315.

- 70) Kinam Park: Targeted delivery to monocytes, *J. Control. Release* 158 (2012) 1.
- 71) Kinam Park: Comparative study on liposome targeting to tumor endothelium, *J. Control. Release* 158 (2012) 181.
- 72) Kinam Park: Intraperitoneal delivery of paclitaxel with injectable hydrogel: “Seeing” is not always “believing”, *J. Control. Release* 158 (2012) 355.
- 73) Kinam Park: Dual drug-eluting stent, *J. Control. Release* 159 (2012) 1.
- 74) Kinam Park: Kinam Park: Arginine-rich CPPs for improved drug delivery to tumors, *J. Control. Release* 159 (2012) 153.
- 75) Kinam Park: Functional enhancement of transplanted islets by extendin-4, *J. Control. Release* 159 (2012) 311.
- 76) Kinam Park: Toxicity risk of nanocarriers, *J. Control. Release* 160 (2012) 1.
- 77) Kinam Park: A two-step external activation for targeted intracellular delivery, *J. Control. Release* 161 (2012) 150.
- 78) Kinam Park: Extravascular transport of nanoparticles in solid tumors, *J. Control. Release* 161 (2012) 967.
- 79) Kinam Park: No penetration of nanoparticles through intact skin, *J. Control. Release* 162 (2012) 258.
- 80) Kinam Park: Active liposomal loading of a poorly soluble ionizable drug. *J. Control. Release* 162 (2012) 475.
- 81) Kinam Park: Significance of handling, formulation and storage conditions on the stability and bioactivity of rhBMP-2. *J. Control. Release* 162 (2012) 654.
- 82) Kinam Park: The role of major vault protein (MVP) in drug resistance. *J. Control. Release* 163 (2012) 266.
- 83) Kinam Park: Vascular modification by electroporation. *J. Control. Release* 163 (2012) 404.
- 84) Kinam Park: Poly-SNO-HSA: A safe and effective multifunctional antitumor agent. *J. Control. Release* 164 (2012) 105.
- 85) Kinam Park: A cell therapy-based cure of the Laron Syndrome. *J. Control. Release* 165 (2013) 90.
- 86) Kinam Park: Targeted delivery nano/micro particles to inflamed intestinal mucosa in human, *J. Control. Release* 165 (2013) 162.
- 87) Kinam Park: Mechanistic study on the ABC phenomenon of PEG conjugates, *J. Control. Release* 165 (2013) 234.
- 88) Kinam Park: Targeted inhibition of inflammatory gene expression in endothelial cells, *J. Control. Release* 166 (2013) 86.

- 89) Kinam Park: Transport of nanostructured lipid carriers across the intestinal barrier, *J. Control. Release* 166 (2013) 195.
- 90) Kinam Park: Not all liposomes are created equal, *J. Control. Release* 166 (2013) 316.
- 91) Kinam Park: Nanoparticle diffusion in the bovine vitreous, *J. Control. Release* 167 (2013) 108.
- 92) Kinam Park: Improved tumor targeting by mild hyperthermia, *J. Control. Release* 167 (2013) 220.
- 93) Kinam Park: Hydrogel particle aggregates for growth factor delivery, *J. Control. Release* 167 (2013) 333.
- 94) Kinam Park: Delivery of definable numbers of PLGA microparticles within embroid bodies, *J. Control. Release* 168 (2013) 103.
- 95) Kinam Park: Protocells for DNA cargo delivery to the spinal cord, *J. Control. Release* 168 (2013) 238.
- 96) Kinam Park: A new look at ultrasound-mediated extravasation, *J. Control. Release* 168 (2013) 341.
- 97) Kinam Park: Just getting into cells is not enough, *J. Control. Release* 169 (2013) 162.
- 98) Kinam Park: Small molecule inhibitors to manipulate adenovirus gene transfer, *J. Control. Release* 170 (2013) 160.
- 99) Kinam Park: Catechol-functionalized adhesive nanoparticles as a surface-releasing system, *J. Control. Release* 170 (2013) 306.
- 100) Kinam Park: Nanospheres for modulating macrophage-specific inflammation, *J. Control. Release* 170 (2013) 487.
- 101) Kinam Park: PK modulation of peptides by hapten-mediated antibody complexation, *J. Control. Release* 171 (2013) 91.
- 102) Kinam Park: Programmed sickle cells for targeted delivery to hypoxic tumors, *J. Control. Release* 171 (2013) 258.
- 103) Kinam Park: Questions on the role of the EPR effect in tumor targeting, *J. Control. Release* 172 (2013) 391.
- 104) Kinam Park: *In vitro* and *in vivo* correlation of paclitaxel-loaded polymeric microparticles, *J. Control. Release* 172 (2013) 1162.
- 105) Kinam Park: Multicomponent nanochains for treating cancer micrometastasis, *J. Control. Release* 173 (2013) 166.
- 106) Kinam Park: Lessons learned from thermosensitive liposomes for improved chemotherapy, *J. Control. Release* 174 (2014) 219.
- 107) Kinam Park: Complex adaptive therapeutic strategy for cancer treatment, *J. Control. Release* 175 (2014) 87.
- 108) Kinam Park: Endothelial specific delivery of siRNA, *J. Control. Release* 176 (2014) 133.

- 109) Kinam Park: Harnessing lipid absorption pathways to target the lymphatic system, *J. Control. Release* 177 (2014) 108.
- 110) Kinam Park: Targeted vs. Non-Targeted Delivery Systems: Reduced Toxicity over Efficacy, *J. Control. Release* 178 (2014) 126.
- 111) Kinam Park: The mitotic window of opportunity for plasmid DNA delivery, *J. Control. Release* 179 (2014) 76.
- 112) Kinam Park: Absence of in vivo - in vitro correlation in per-oral drug delivery, *J. Control. Release* 180 (2014) 150.
- 113) Kinam Park: Cornea-targeted gene therapy using adenovirus vector, *J. Control. Release* 181 (2014) 53.
- 114) Kinam Park: Collagen gels for delivery of bioactive peptide derived from BMP-9, *J. Control. Release* 182 (2014) 12.
- 115) Kinam Park: Biological effect of BMP-2 monitored by PET/CT, *J. Control. Release* 183 (2014) 178.
- 116) Kinam Park: Vascularization in 3D bioprinted scaffolds, *J. Control. Release* 184 (2014) 79.
- 117) Kinam Park: Lyotropic liquid crystal for long-term delivery of peptide drugs, *J. Control. Release* 185 (2014) 139.
- 118) Kinam Park: Reversible albumin conjugation for improved molecular imaging, *J. Control. Release* 186 (2014) 88.
- 119) Kinam Park: True combination therapy using synergistic drug combination, *J. Control. Release* 187 (2014) 198.
- 120) Kinam Park: Dissolution mechanisms of felodipine solid dispersions, *J. Control. Release* 188 (2014) 101.
- 121) Kinam Park: Translation from mouse to human: Time to think in new boxes, *J. Control. Release* 189 (2014) 187.
- 122) Kinam Park: Predictive models of nanoparticle transport in solid tumors, *J. Control. Release* 192 (2014) 325.
- 123) Kinam Park: Ligand Affinity: Multivalency counterbalances PEGylation, *J. Control. Release* 194 (2014) 351.
- 124) Kinam Park: Rhythmomimetic Drug Delivery, *J. Control. Release* 196 (2014) 394.
- 125) Kinam Park: Antibody transport within the brain, *J. Control. Release* 197 (2014) 219.
- 126) Kinam Park: Triglyceride micro-emulsion for detoxification of acute pharmacotoxicity, *J. Control. Release* 198 (2014) 104.

- 127) Kinam Park: Tissue penetration of bacteria into quiescent regions of tumors, *J. Control. Release* 199 (2015) 198.
- 128) Kinam Park: Quantitative 3D mapping of drug absorption in skin, *J. Control. Release* 200 (2015) 233.
- 129) Kinam Park: A microfluidic system for evaluating drug delivery to solid tumors, *J. Control. Release* 201 (2015) 101.
- 130) Kinam Park: Mast cells for cell-mediated therapy, *J. Control. Release* 202 (2015) 118.
- 131) Kinam Park: Calcium–siRNA nanocomplexes: The importance of reversibility, *J. Control. Release* 203 (2015) 189.
- 132) Kinam Park: Thin-film freeze-drying for lyophilization of vaccines, *J. Control. Release* 204 (2015) 98.
- 133) Kinam Park: Insight into extravasation and internalization of nanoparticles, *J. Control. Release* 206 (2015) 243.
- 134) Kinam Park: Spatio-temporal heterogeneity in tumor liposome uptake: characterization of macro- and microdistribution, *J. Control. Release* 207 (2015) 165.
- 135) Kinam Park: Biodegradable thermosensitive polymer gel for sustained BMP-2 delivery, *J. Control. Release* 209 (2015) 337.
- 136) Kinam Park: Rational design of agents to transiently increase paracellular permeability, *J. Control. Release* 210 (2015) 246.
- 137) Kinam Park: Drug release mechanisms from amorphous solid dispersions, *J. Control. Release* 211 (2015) 171.
- 138) Kinam Park: Opening the blood-brain barrier by focused ultrasound, *J. Control. Release* 212 (2015) 113.
- 139) Kinam Park: An intravaginal ring for sustained and simultaneous delivery of 4 drugs, *J. Control. Release* 213 (2015) 193.
- 140) Kinam Park: Super paramagnetic nanoparticles for the diagnostic imaging of pancreatic cancer, *J. Control. Release* 214 (2015) 134.
- 141) Kinam Park: Enhanced regeneration capacity of cardiac stem cells by TAT-Hsp27, *J. Control. Release* 215 (2015) 129.
- 142) Kinam Park: Dynamic cell culture model of endothelial cells for simulating in vivo nanoparticle uptake, *J. Control. Release* 216 (2015) 169.
- 143) Kinam Park: 3D printing of 5-drug polypill, *J. Control. Release* 217 (2015) 352-253.
- 144) Kinam Park: IVIVC of parenteral PLGA microspheres, *J. Control. Release* 218 (2015) 116.
- 145) Kinam Park: Novel approach to measure drug release from nanomedicines, *J. Control. Release* 220 (2015) 568.

- 146) Kinam Park: An integrated assessment of PEGylated liposomal doxorubicin products, *J. Control. Release* 221 (2015) 71.
- 147) Kinam Park: Exosome-based therapeutic approach for muscle regeneration, *J. Control. Release* 222 (2016) 176.
- 148) Kinam Park: Targeting prostate cancer cells en route to dissemination, *J. Control. Release* 223 (2016) 224.
- 149) Kinam Park: A hydrophilic matrix approach for controlled vaginal drug delivery, *J. Control. Release* 224 (2016) 240.
- 150) Kinam Park: Dissolving microneedle vaccine delivery system, *J. Control. Release* 225 (2016) 314.
- 151) Kinam Park: Isolated lung model for assessing drug absorption from PLGA microparticle, *J. Control. Release* 226 (2016) 268.
- 152) Kinam Park: Magnetic resonance imaging for developing intramuscular formulations, *J. Control. Release* 227 (2016) 94.
- 153) Kinam Park: Enhanced antitumor effects of hTRAIL by binding to endogenous albumin, *J. Control. Release* 228 (2016) 206.
- 154) Kinam Park: Visualization of focal permeation sites within epithelial barriers, *J. Control. Release* 229 (2016) 200.
- 155) Kinam Park: Sustained delivery of antibodies in vivo by local retention, *J. Control. Release* 230 (2016) 116.
- 156) Kinam Park: Enhanced antitumor effects of hTRAIL by binding to endogenous albumin, *J. Control. Release* 232 (2016) 265.
- 157) Kinam Park: Organotypic non-melanoma skin cancer models for use in preclinical research, *J. Control. Release* 233 (2016) 220.
- 158) Kinam Park: Pulmonary delivery of anti-ricin antibody: From the bench to the clinic, *J. Control. Release* 234 (2016) 135.
- 159) Kinam Park: Sustained efficacy of paclitaxel nanocrystals in hydrogel depot, *J. Control. Release* 235 (2016) 393.
- 160) Kinam Park: Acoustic Cluster Therapy for better treatment of solid tumors, *J. Control. Release* 236 (2016) 117.
- 161) Kinam Park: Mechanisms controlling drug release from coated pellets, *J. Control. Release* 237 (2016) 185.
- 162) Kinam Park: Maintaining protein activity during hydrogel cross-linking, *J. Control. Release* 238 (2016) 313.

- 163) Kinam Park: Hemocompatible and immune-safe library of citrem-phospholipid liquid crystalline nanoplatfoms, *J. Control. Release* 239 (2016) 249.
- 164) Kinam Park: In vivo DNA delivery with NickFect peptide vectors, *J. Control. Release* 241 (2016) 242.
- 165) Kinam Park: Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer, *J. Control. Release* 243 (2016) 381.
- 166) Kinam Park: Ocular microparticle formulations for 6-month delivery of anti-VEGF, *J. Control. Release* 244 (2016) 136.
- 167) Kinam Park: The drug delivery field needs a well-diversified technology portfolio, *J. Control. Release* 245 (2016) in press.